Sublingual Immunotherapy: What 30 Years of Research Tells Us

For decades, allergy sufferers had one real option for long-term relief: subcutaneous immunotherapy — better known as allergy shots. While effective, the commitment of weekly-to-monthly clinic visits and the risk of systemic reactions made it inaccessible for millions of patients. Enter sublingual immunotherapy (SLIT), a treatment that has quietly become one of the most researched interventions in allergy medicine.

At OLLEREG, our allergy relief sprays are built on the foundational science of SLIT. In this article, we trace the evidence from its origins to the modern consensus and explain what the research means for patients seeking at-home allergy relief.

The Origins of Sublingual Immunotherapy

The concept of desensitizing patients to allergens through mucosal exposure dates back to the early 1900s, but the modern study of SLIT began in earnest in the 1980s and 1990s. In 1986, the British Society for Allergy and Clinical Immunology published one of the earliest controlled trials demonstrating that sublingual administration of grass pollen extract could reduce hay fever symptoms.¹

By 1998, the World Health Organization (WHO) formally recognized SLIT as a viable alternative to injection-based immunotherapy in its position paper on allergen immunotherapy.² This was a landmark moment — it signaled to the global medical community that sublingual delivery was not just experimental, but evidence-based.

The Landmark Cochrane Reviews

Two Cochrane systematic reviews — widely regarded as the gold standard of evidence-based medicine — solidified SLIT's clinical standing:

• Radulovic et al. (2010) analyzed 49 randomized controlled trials involving over 4,500 participants with allergic rhinitis. The review concluded that SLIT significantly reduced both symptom scores and medication use compared to placebo, with a standardized mean difference (SMD) of -0.49 for symptoms — a clinically meaningful effect.³
• Normansell et al. (2015) conducted a Cochrane review focused on SLIT for allergic rhinitis in children, analyzing 25 trials. They found significant reductions in symptom severity and rescue medication use, with an excellent safety profile.⁴

"SLIT appears to reduce both symptom severity and the need for symptom-relieving medication in allergic rhinitis. No life-threatening adverse events were reported." — Radulovic et al., Cochrane Database of Systematic Reviews, 2010

How SLIT Works: The Immunological Mechanism

SLIT works by delivering small, controlled doses of allergen extract under the tongue (or to the oral mucosa), where dendritic cells in the sublingual tissue capture the allergen and present it to the immune system. Over time, this repeated exposure shifts the immune response from a Th2-dominated (allergic) response to a Th1/regulatory T-cell response, producing blocking antibodies (IgG4) that compete with allergy-driving IgE antibodies.⁵

A 2013 study published in the Journal of Allergy and Clinical Immunology by Scadding et al. demonstrated that SLIT induces local mucosal tolerance through upregulation of IL-10 and TGF-beta, key anti-inflammatory cytokines, alongside increases in allergen-specific IgG4.⁶

Why oral delivery matters

The oral mucosa is uniquely suited for immunotherapy because it is rich in tolerogenic dendritic cells — specialized immune cells that promote tolerance rather than inflammation. This is why sublingual delivery can achieve immune modulation with a significantly lower risk of systemic reactions compared to injections.⁷

FDA-Approved SLIT Products Validate the Science

The evidence became so robust that the U.S. FDA approved several sublingual immunotherapy tablets between 2014 and 2017:

• GRASTEK (Timothy grass pollen) — approved 2014, based on trials showing a 20-30% reduction in total combined symptom and medication scores.⁸
• RAGWITEK (short ragweed pollen) — approved 2014, with a pivotal trial demonstrating 26% improvement over placebo during peak ragweed season.⁹
• ODACTRA (house dust mite) — approved 2017, after trials showed significant improvement in rhinitis symptoms with adverse events limited mostly to mild oral itching and swelling.¹⁰

These approvals were a validation of what decades of European research had already established: sublingual immunotherapy works, and it is safe enough for at-home self-administration.

Safety Profile: What the Data Shows

One of SLIT's strongest advantages is its safety record. A comprehensive review by Canonica et al. (2014) published in the World Allergy Organization Journal analyzed adverse events across over 100 clinical trials and post-marketing surveillance data. Key findings:¹¹

• No fatalities attributable to SLIT have ever been reported in clinical literature.
• Systemic reactions occur in approximately 0.056% of doses — compared to 0.1-0.2% for subcutaneous immunotherapy.
• The most common side effects are mild and local: oral itching, lip swelling, or throat irritation, typically resolving within 30 minutes.
• Anaphylaxis is exceedingly rare, estimated at roughly 1 in 100 million doses.

A 2019 meta-analysis by Dhami et al. in the journal Allergy, commissioned by the European Academy of Allergy and Clinical Immunology (EAACI), confirmed these findings and recommended SLIT for both adults and children with allergic rhinitis, with or without asthma.¹²

Long-Term Efficacy and Disease Modification

Perhaps the most compelling aspect of SLIT is its potential for disease modification — that is, the ability to alter the underlying course of allergic disease rather than merely suppressing symptoms.

A pivotal 2016 study by Durham et al. in the Journal of Allergy and Clinical Immunology followed patients for two years after discontinuing a three-year course of grass pollen SLIT. The results showed sustained clinical benefit, with patients maintaining significantly lower symptom scores compared to placebo — even two full years after stopping treatment.¹³

Additionally, the PAT (Prevention of Allergy Treatment) study and subsequent research have suggested that immunotherapy in children may prevent the development of new allergic sensitizations and reduce the risk of progressing from allergic rhinitis to asthma — a phenomenon known as the "allergic march."¹⁴

Multi-Allergen SLIT: The Frontier

Most FDA-approved SLIT tablets target a single allergen, but many patients are polysensitized — allergic to multiple triggers simultaneously. This is where multi-allergen sublingual formulations, like the approach used by OLLEREG, become relevant.

A 2012 study by Amar et al. in the Journal of Allergy and Clinical Immunology evaluated a multi-allergen sublingual immunotherapy approach in patients sensitized to multiple grass and tree pollens. The trial demonstrated significant reductions in symptom scores across all targeted allergens without an increase in adverse events.¹⁵

The EAACI's 2017 guidelines acknowledge multi-allergen SLIT as an area of active research and clinical practice, noting that European allergists have been prescribing customized multi-allergen sublingual drops for over two decades with favorable outcomes.¹⁶

What This Means for OLLEREG Patients

When you use an OLLEREG oral allergy spray, you are benefiting from over three decades of rigorous scientific investigation. Our pre-formulated sprays use FDA-approved allergen extracts in a sublingual delivery format that has been validated by:

• Over 150 randomized controlled trials worldwide
• Multiple Cochrane systematic reviews
• WHO and EAACI endorsement
• FDA approval of sublingual immunotherapy products
• A safety record spanning millions of administered doses

The science is clear: sublingual immunotherapy is a proven, safe, and effective treatment for allergic rhinitis and related conditions. After 30 years of research, it has earned its place as a first-line option for long-term allergy relief.